TTToshiaki Tanaka

Toshiaki Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toshiaki Tanaka has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Reiko Horikawa

    Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan

    3 shared publications
  • Koji Moriya

    Department of Life Science and Technology Institute of Science Tokyo Yokohama‐shi Kanagawa Japan

    2 shared publications
  • Naomi Kitamura

    Authors' Affiliations: 1Department of Biological Sciences, Graduate School of Bioscience and Biotechnology and 2Department of Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan; 3Department of Inorganic Materials, Graduate School of Engineering, Tokyo Institute of Technology

    2 shared publications
  • Tomio Hashimoto

    Authors' Affiliations: 1Department of Biological Sciences, Graduate School of Bioscience and Biotechnology and 2Department of Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan; 3Department of Inorganic Materials, Graduate School of Engineering, Tokyo Institute of Technology

    2 shared publications
  • Toshiyuki Ikoma

    School of Materials and Chemical Technology, Tokyo Institute of Technology, Tokyo, Japan

    2 shared publications
  • Aase Hvidt

    Department of Chemistry, University of CopenhagenCopenhagen Ø, DK-2100 , Denmark

    1 shared publication

Latest Publications

  • Open Access

    Senescence in Normal Human Dermal Fibroblasts Induces Heterogeneous Fibril Orientation of Type I Collagen Through Downregulation of BMP ‐1

    by Koji Moriya, Yuki Shibaike, Katsura Sano, Toshiaki Tanaka

    Considering that the body accumulates senescent fibroblasts during the progression of aging, the character of collagen fibrils secreted from the senescent cells associates with the skin condition. In this study, we examined the alteration of collagen fibrogenesis using groups of normal human dermal fibroblasts with different cumulative population doubling levels (PDLs). We found that the density of extracellular collagen fibrils in late PDLs was lower than that in early or middle PDLs, and their orientation was disturbed in late PDLs. Visualized type I procollagen imaging indicated that cells in late PDLs had a defect in the C‐terminal propeptide (C‐pp) cleavage of procollagen. Biochemical analyses confirmed decreases in intracellular C‐pp and extracellular collagen accompanied by PDL progression. Cells in late PDLs downregulated BMP‐1 and PCPE‐1, and BMP‐1 knockdown in cells of early PDLs decreased the amount of extracellular collagen and disturbed the fibril orientation. These fibrils contained more C‐pp than the control fibrils. Our results showed that cell senescence decreases C‐pp cleavage and secretion of type I collagen through downregulation of BMP‐1, resulting in the accumulation of extracellular procollagen and loss of fibril orientation.


  • Open Access

    Visualized procollagen Iα1 demonstrates the intracellular processing of propeptides

    by Toshiaki Tanaka, Koji Moriya, Makoto Tsunenaga, Takayo Yanagawa, Hiromi Morita, Takashi Minowa, Yoh-Ichi Tagawa, Nobutaka Hanagata, Yutaka Inagaki, Toshiyuki Ikoma

    The processing of type I procollagen is essential for fibril formation; however, the steps involved remain controversial. We constructed a live cell imaging system by inserting fluorescent proteins into type I pre-procollagen α1. Based on live imaging and immunostaining, the C-propeptide is intracellularly cleaved at the perinuclear region, including the endoplasmic reticulum, and subsequently accumulates at the upside of the cell. The N-propeptide is also intracellularly cleaved, but is transported with the repeating structure domain of collagen into the extracellular region. This system makes it possible to detect relative increases and decreases in collagen secretion in a high-throughput manner by assaying fluorescence in the culture medium, and revealed that the rate-limiting step for collagen secretion occurs after the synthesis of procollagen. In the present study, we identified a defect in procollagen processing in activated hepatic stellate cells, which secrete aberrant collagen fibrils. The results obtained demonstrated the intracellular processing of type I procollagen, and revealed a link between dysfunctional processing and diseases such as hepatic fibrosis.


  • Open Access

    Phase 3 Study Evaluating Once Weekly Somatrogon Compared to Daily Genotropin in Japanese Patients With Pediatric Growth Hormone Deficiency (pGHD)

    by Reiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, Tohru Yorifuji, David Ng, Ron G Rosenfeld, Yuko Hoshino, Akifumi Okayama, Daisuke Shima, Roy Gomez, et al.

    Objectives: Somatrogon is a long-acting recombinant human growth hormone consisting of the amino acid sequence of human growth hormone and three copies of the carboxy-terminal peptide of human chorionic gonadotropin. Somatrogon is being developed as a once weekly treatment for children with pGHD. A Phase 3 trial was designed to compare the efficacy and safety of somatrogon administered once weekly with Genotropin administered once daily in Japanese patients with pGHD (ClinicalTrials. gov: NCT03874013). Methods: 44 Japanese pGHD patients (age 3-11 years) were randomized in a 1:1 ratio to receive either once weekly somatrogon (0.66 mg/kg/week) or once daily Genotropin (0.025 mg/kg/day) subcutaneously for 12 months. Somatrogon-treated patients had a pharmacokinetic assessment in the first 6 weeks with dose escalation occurring in 3 steps, at 0.25, 0.48, and 0.66 mg/kg/week, for 2 weeks at each dose. For the remaining 46 weeks, patients in the somatrogon treatment group continued to receive somatrogon at a dose of 0.66 mg/kg/week. The primary endpoint of the study was annualized height velocity (HV) at 12 months. Results: Baseline characteristics were balanced and comparable between the two treatment groups. The least square means of HV at month 12 were 9.65 cm/year in the somatrogon group (n=22) and 7.87 cm/year in the Genotropin group (n=22), with a point estimate treatment difference of 1.79 cm/year (95% confidence interval: 0.97, 2.60) in favour of somatrogon. The point estimate was greater than the pre-established mean treatment difference of -1.8 cm/year, which was the non-inferiority margin met in the global Phase 3 study (n=224) with somatrogon (0.66 mg/kg/week) and Genotropin (0.034mg/kg/day) (ClinicalTrials. gov: NCT02968004). Most of the adverse events were mild to moderate in severity and somatrogon was generally well-tolerated with no notable difference in safety between the two treatment groups. Injection site pain was more common in the somatrogon group (somatrogon: 72.7%, Genotropin: 13.6%). Conclusions: The Japanese Phase 3 trial in patients with pGHD demonstrated that once weekly somatrogon was comparable to daily Genotropin. The annual HV after 12 months of treatment was higher in the somatrogon group than the Genotropin group. Somatrogon administration was generally well tolerated in patients with pGHD. The results of this Japanese Phase 3 study are consistent with the results previously reported from the global Phase 3 study that met its primary endpoint of noninferiority to daily Genotropin.


  • Genes coding for cyclin-dependent kinase inhibitors are fragile in Xenopus

    by Toshiaki Tanaka, Haruki Ochi, Shuji Takahashi, Naoto Ueno, Masanori Taira


  • Open Access

    ERK-Dependent Downregulation of Skp2 Reduces Myc Activity with HGF, Leading to Inhibition of Cell Proliferation through a Decrease in Id1 Expression

    by Xiaoran Li, Ying Bian, Yuri Takizawa, Tomio Hashimoto, Toshiyuki Ikoma, Junzo Tanaka, Naomi Kitamura, Yutaka Inagaki, Masayuki Komada, Toshiaki Tanaka

    Hepatocyte growth factor (HGF) has an inhibitory effect on human HepG2 hepatoma cell proliferation. Previously, it was shown that HGF treatment downregulated Id1 and upregulated p16INK4a in an ERK-dependent manner, leading to the inhibition of cellular proliferation. Here, new insight suggests that Skp2, an SCF complex component and potential prognosticator in cancer, is downregulated by injection of HGF into established HepG2 xenograft tumors. The downregulation was evident at both the mRNA and protein level and in an ERK-dependent manner. Critically, high expression of Skp2 restored HGF-inhibited cell proliferation, indicating that the inhibitory effect of HGF required the downregulation of Skp2. However, downregulation was not involved in the HGF-induced upregulation of a CDK inhibitor, p27Kip1, a known SCF-Skp2 target. Instead, data revealed that Skp2 regulated Myc activity, which has oncogenic potential in the generation of hepatocellular carcinoma. Elevated expression of Skp2 or a mutant that is unable to associate with the SCF complex was capable of activating Myc, suggesting that Skp2 does not act on Myc as a component of the SCF complex, and thus functions as an activator of Myc independent of its role in ubiquitination. Furthermore, Skp2 regulated Id1 expression by regulating Myc activity, and the regulation of Skp2 is involved in the activity of p16 promoter through regulation of Id1 expression. Overall, these mechanistic findings provide the first evidence that ERK-dependent downregulation of Skp2 reduced Myc activity, leading to HGF-induced inhibition of cell proliferation through decreased Id1 expression. Implications: This study elucidates the molecular details of HGF-induced inhibition of cellular proliferation in liver cancer cells. Mol Cancer Res; 11(11); 1437–47. ©2013 AACR.


  • Induction of mitochondrial uncoupling enhances VEGF120 but reduces MCP-1 release in mature 3T3-L1 adipocytes: Possible regulatory mechanism through endogenous ER stress and AMPK-related pathways

    by Kaoru Miyokawa-Gorin, Kazuto Takahashi, Keiko Handa, Atsuko Kitahara, Yoshikazu Sumitani, Hidenori Katsuta, Toshiaki Tanaka, Susumu Nishida, Katsuhiko Yoshimoto, Hideki Ohno, et al.


  • Open Access

    Id1 Is Down-Regulated by Hepatocyte Growth Factor via ERK-Dependent and ERK-Independent Signaling Pathways, Leading to Increased Expression of p16INK4a in Hepatoma Cells

    by Kazutaka Ushio, Tomio Hashimoto, Naomi Kitamura, Toshiaki Tanaka

    Hepatocyte growth factor (HGF) inhibits the proliferation of several tumor cell lines and tumor growth in vivo. We showed previously that HGF induces cell cycle arrest at G1 in a human hepatoma cell line, HepG2, by up-regulating the expression of p16INK4a through strong activation of extracellular signal-regulated kinase (ERK). However, although essential, the activation was not sufficient for the up-regulation of p16. In this study, we examined regulatory mechanisms of p16 expression through a transcription factor, Ets, which has been shown previously to bind to the promoter. The treatment of HepG2 cells with HGF induced ERK-dependent phosphorylation of Ets, which leads to its activation, before the up-regulation of p16, suggesting that another factor suppresses Ets activity. We found that HGF reduces the amount of Id1, which is a dominant-negative inhibitor of Ets, leading to a decrease in Ets associated with Id1. Id1 was down-regulated via transcriptional regulation not via the ubiquitin-proteasome-mediated pathway. Inhibition of the HGF-induced high-intensity ERK activity had a modest effect on the Id1 down-regulation, and inhibition of the phosphatidylinositol 3-kinase pathway had no effect, showing that Id1 is regulated by ERK-dependent and -independent pathways other than the phosphatidylinositol 3-kinase pathway. Exogenously expressed Id1 suppressed the up-regulation of p16 by HGF and the antiproliferative effect of HGF. Knockdown of Id1 significantly enhanced the activity of the p16 promoter coordinately with the activation of ERK. Our results indicated that down-regulation of Id1 plays a key role in the inhibitory effect of HGF on cell proliferation and provides a molecular basis for cancer therapy with HGF. (Mol Cancer Res 2009;7(7):1179–88)


  • Inconsistent determination of overweight by two anthropometric indices in girls with Turner syndrome

    by Tsuyoshi Isojima, Susumu Yokoya, Junko Ito, Reiko Horikawa, Toshiaki Tanaka

    Aim: To evaluate the prevalence of overweight in girls with Turner syndrome (TS) as classified by the two major anthropometric indices, body mass index (BMI) and weight‐for‐height (WFH) and to make growth reference charts of them for comparison with those of the normal population.Method: The samples for analysis were obtained from a retrospective cohort. In total, 1447 girls' cross‐sectional data were analysed. Subjects were divided into four groups by ages: group A (0–5.99 years), B (6–10.99 years), C (11–15.99 years) and D (16–20.99 years). The cut‐off values of overweight by BMI and WFH were those of the 90th percentile and 120 percent, respectively and the prevalence was calculated. For constructing growth reference charts, the LMS method was used.Results: The prevalence of overweight differed between the two indices. The proportions of the coincidental classification in all subjects, group A, B, C and D were 82.53%, 89.96%, 91.79%, 69.98% and 60.61%, respectively. These differences corresponded to the difference of age‐dependent patterns of the two indices from those of the normal population, as judged from the growth charts constructed with all subjects.Conclusion: A discrepancy in the prevalence of overweight as classified by BMI and WFH for girls with TS was detected.


  • Up‐regulation of p21CIP1 expression mediated by ERK‐dependent and ‐independent pathways contributes to hepatocyte growth factor‐induced inhibition of HepG2 hepatoma cell proliferation

    by Erika Shirako, Naoki Hirayama, Yu‐Ichi Tsukada, Toshiaki Tanaka, Naomi Kitamura

    Strong activation of the ERK signal is required for hepatocyte growth factor (HGF) to inhibit proliferation of the human hepatocellular carcinoma cell line HepG2. However, it is still to be elucidated whether the activation alone is sufficient to induce the inhibitory effect. In this study, we constructed HepG2 cell clones expressing a high level of epidermal growth factor receptor (EGFR), and examined the effect of the strong activation of ERK on the proliferation of the cell clones. EGF treatment of the cell clones induced strong activation of ERK similar to HGF treatment, but did not inhibit cell proliferation. HGF treatment of the cell clones up‐regulated the expression of a Cdk inhibitor p16INK4a, which has previously been shown to be required to inhibit the proliferation of HepG2 cells, but EGF treatment did not. Furthermore, EGF treatment of the cell clones did not induce the up‐regulation of another Cdk inhibitor p21CIP1, whereas HGF treatment did. Knockdown of p21 by siRNA restored the proliferation of HepG2 cells inhibited by HGF, and restored Cdk2 activity suppressed in HGF‐treated HepG2 cells. These results suggest that strong activation of ERK alone is not sufficient, and some other pathway(s), which is activated through the HGF receptor but not through EGFR, is also required to induce the up‐regulation of p16 and p21 expression, and also suggest that in addition to the up‐regulated expression of p16, that of p21 contributes to the suppression of Cdk2 activity leading to the inhibition of proliferation of HGF‐treated HepG2 cells. J. Cell. Biochem. 104: 176–188, 2008.


  • Open Access

    Three Patients with Autism and Central Precocious Puberty

    by Kazuko Yoshimura, Yasuhiro Naiki, Reiko Horikawa, Toshiaki Tanaka